Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21350707 | 0.90 | SMYD3 (0.41) | SMYD3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7864214 | 0.84 | FKBP1A (0.43) | SMYD3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19734038 | 0.83 | ALDH1A1 (0.44) | SMYD3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19734075 | 0.81 | SMYD3 (0.43) | SMYD3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19734197 | 0.81 | SMYD3 (0.44) | SMYD3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8817322 | 0.80 | FKBP1A (0.44) | SMYD3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL10289670 | 0.79 | SMYD3 (0.43) | SMYD3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL30621167 | 0.77 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL19734176 | 0.75 | SMYD3 (0.41) | SMYD3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19734105 | 0.75 | SMYD3 (0.48) | SMYD3PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | Epizyme, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20170362217-A1 | Substituted Piperidine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | SMYD3, SMYD2, SNRPD3 | SMYD3 1/4885PSEN1 3230/4885PSEN2 2279/4885 |
| US-20170362217-A1 | Substituted Piperidine Compounds | SMYD3, SMYD2, SNRPD3 | SMYD3 1/4885PSEN1 3230/4885PSEN2 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.